These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23183689)

  • 1. Modelling approaches for bio-manufacturing operations.
    Chhatre S
    Adv Biochem Eng Biotechnol; 2013; 132():85-107. PubMed ID: 23183689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tableting process optimisation with the application of fuzzy models.
    Belic A; Skrjanc I; Bozic DZ; Vrecer F
    Int J Pharm; 2010 Apr; 389(1-2):86-93. PubMed ID: 20096760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic modelling of fluidized bed drying processes of wet porous granules: a review.
    Mortier ST; De Beer T; Gernaey KV; Remon JP; Vervaet C; Nopens I
    Eur J Pharm Biopharm; 2011 Oct; 79(2):205-25. PubMed ID: 21664970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of large eddy simulation in industrial practice: challenges and opportunities.
    Hutton AG
    Philos Trans A Math Phys Eng Sci; 2009 Jul; 367(1899):2819-26. PubMed ID: 19531504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling iterative compound optimisation using a self-avoiding walk.
    Delaney J
    Drug Discov Today; 2009 Feb; 14(3-4):198-207. PubMed ID: 19027874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimisation of the capping tendency by tableting process optimisation with the application of artificial neural networks and fuzzy models.
    Belic A; Skrjanc I; Bozic DZ; Karba R; Vrecer F
    Eur J Pharm Biopharm; 2009 Sep; 73(1):172-8. PubMed ID: 19465122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput process development for biopharmaceutical drug substances.
    Bhambure R; Kumar K; Rathore AS
    Trends Biotechnol; 2011 Mar; 29(3):127-35. PubMed ID: 21255855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appraisal of chlorine contact tank modelling practices.
    Rauen WB; Angeloudis A; Falconer RA
    Water Res; 2012 Nov; 46(18):5834-47. PubMed ID: 22963866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
    Federsel HJ
    Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medium term planning of biopharmaceutical manufacture using mathematical programming.
    Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effective G-CSF therapy strategies for cyclical neutropenia: mathematical modelling based hypotheses.
    Foley C; Bernard S; Mackey MC
    J Theor Biol; 2006 Feb; 238(4):754-63. PubMed ID: 16115650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SysBioMed report: advancing systems biology for medical applications.
    Wolkenhauer O; Fell D; De Meyts P; Blüthgen N; Herzel H; Le Novère N; Höfer T; Schürrle K; van Leeuwen I
    IET Syst Biol; 2009 May; 3(3):131-6. PubMed ID: 19449974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report.
    Karanth H; Shenoy VS; Murthy RR
    AAPS PharmSciTech; 2006 Oct; 7(4):87. PubMed ID: 17233539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active pharmaceutical ingredient (API) production involving continuous processes--a process system engineering (PSE)-assisted design framework.
    Cervera-Padrell AE; Skovby T; Kiil S; Gani R; Gernaey KV
    Eur J Pharm Biopharm; 2012 Oct; 82(2):437-56. PubMed ID: 22820647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.